Piramal Pharma Limited
Indian Pharmaceutical Exporter · Cardiovascular Specialist · $64.5M Total Trade · DGFT Verified
Piramal Pharma Limited is an Indian pharmaceutical exporter with a total trade value of $64.5M across 8 products in 5 therapeutic categories. Based on 1,328 verified export shipments from Indian Customs (DGFT) records, Piramal Pharma Limited is the #1 Indian exporter in 1 product including Ezetimibe. Top exports include Atorvastatin ($21.4M), Calcium ($14.4M), Ezetimibe ($13.4M).
Piramal Pharma Limited — Export Portfolio & Destination Treemap

Who is Piramal Pharma Limited? — Company Overview & Market Position
Piramal Pharma Limited (PPL) was established on March 4, 2020, as a demerged entity from Piramal Enterprises, marking its emergence as a standalone pharmaceutical company. Headquartered in Mumbai, Maharashtra, PPL operates as a public limited company with the Corporate Identification Number (CIN) U24297MH2020PLC338592. The company is a subsidiary of the Piramal Group, a diversified conglomerate with interests spanning pharmaceuticals, financial services, and real estate. The Piramal Group has a global presence, operating in over 30 countries and more than 100 markets, with a workforce of over 10,000 employees from 21 diverse nationalities.
In the fiscal year 2024, PPL reported a revenue of ₹8,605 crore, with a net operating income of ₹8,171 crore. The company's assets stood at ₹12,822 crore, and it achieved a profit of ₹18 crore, resulting in a net worth of ₹7,911 crore. As of March 2026, PPL employs approximately 5,476 individuals, reflecting its significant role in the pharmaceutical industry. The company's official website is www.piramalpharma.com.